Phase 2 N=212 Residual Effects of Intoxication on Student Performance
Alcoholic Intoxication · Neurobehavioral Manifestations
Primary: Self-reported Residual Effects of Heavy Drinking — 4.3; 1.93 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=2,428 VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
Zika Virus · Zika Virus Infection · Virus Diseases
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) — 5; 2; 2; 291 Participants
Phase 2 N=40 Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant
Multiple Myeloma
Primary: Participants With Id-specific Immunity — 0; 8 Participants
Phase 2 N=395 Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic Steatohepatitis
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) — 84.6; 85.0; 92.5; 88.6 percentage of participants
Phase 2 N=5 MMF for HIV Reservoir Reduction
Human Immunodeficiency Virus I Infection
Primary: Change in Cell-associated HIV DNA (Ca-DNA) Levels Per 10^6 T Cells Over 12 Months — -0.00033 log10 caDNA copies per 10^6 T-cells/week
Phase 2 N=120 To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin
Androgenic Alopecia
Primary: Scalp Hair Density — 1.46; 2.58; -4.10; 6.68 Change from baseline (No. of hairs/cm2)
Phase 2 N=45 Evaluation of Oral Plaque Removal Utilizing an Adjunct Enzyme Pre-rinse
Dental Plaque · Dental Caries
Primary: Composite Plaque Score — 36.2; 37.9 score on a scale — p=.044
Phase 2 N=789 Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF
Chronic Heart Failure With Preserved Ejection Fraction
Primary: Change in KCCQ Physical Limitation Score From Baseline to Week 24 — 6.41; 5.47; 6.93 Scores on a scale — p== 0.8008
Phase 2 N=220 Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
Leukemia · Acute Lymphoblastic Leukemia
Primary: Number of Participants With a Response — 198; 3; 4 Participants
Phase 2 N=39 Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults
Lipoprotein Metabolism · PCSK9 · Proteomics
Primary: Plasma PCSK9 Levels at Baseline and End of 6 Week Intervention — 13.30; 14.11; 12.44 ng/mL
Phase 2 N=62 Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-Free Survival Rate at 16 Weeks Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or…
Phase 2 N=79 Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)
HIV · HIV Infections
Primary: Percentage of Participants With ≥1 Adverse Events (AEs) — 91 Percentage of Participants
Phase 2 N=102 A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder
Major Depression
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part A — 92.3 percentage of participants
Phase 2 N=68 Bevacizumab Beyond Progression (BBP)
Malignant Glioma · Grade 4 Malignant Glioma · Glioblastoma
Primary: Overall Survival — 17.8 months
Phase 2 N=100 Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
Chemotherapeutic Agent Toxicity · Colorectal Cancer · Diarrhea
Primary: Number of Participants With Grade 3/4 Diarrhea — 27; 26; 7; 3 Participants